Deuterated alvocidib and alvocidib prodrugs
AssigneeSumitomo Dainippon Pharma Oncology, Inc.
InventorAdam SIDDIQUI-JAIN
Life of this patent
Estimating the term…
Abstract
Provided herein are compounds having the following structure (I) or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, Ra, Rb, and Rc are as defined herein. Also provided are pharmaceutical compositions comprising compounds of structure (I), or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, and methods for use of compounds of structure (I), or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, for treating diseases associated with overexpression of a cyclin-dependent kinase (CDK).
Claims27
A compound having the following structure (I):
- or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein:
- Ra, Rb and Rc are each independently H, D or —P(═O)(OR)2;
- R, R1, R2, R3, R4 and R5 are, at each occurrence, independently H or D;
- wherein at least one occurrence of R, Ra, Rb, Rc, R1, R2, R3, R4 and R5 is D.
-27. (canceled)
-33. (canceled)
A pharmaceutical composition comprising a pharmaceutically acceptable carrier or excipient, and a compound having the following structure (I):
- or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein:
- Ra, Rb and Rc are each independently H, D or —P(═O)(OR)2,
- R, R1, R2, R3, R4 and R5 are, at each occurrence, independently H or D,
- wherein at least one occurrence of R, Ra, Rb, Rc, R1, R2, R3, R4 and R5 is D.
(canceled)
A method for treating a disease associated with overexpression of a cyclin-dependent kinase (CDK) in a mammal in need thereof, the method comprising administering a therapeutically effective amount of a compound to the mammal, the compound having the following structure (I):
- or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein:
- Ra, Rb and Rc are each independently H, D or —P(═O)(OR)2;
- R, R1, R2, R3, R4 and R5 are, at each occurrence, independently H or D;
- wherein at least one occurrence of R, Ra, Rb, Rc, R1, R2, R3, R4 and R5 is D.
40-43. (canceled)
(canceled)
(canceled)
-54. (canceled)
(canceled)
Dependencies are inferred from the claim text.